The new cardiovascular death risk reduction indication on the US label of Boehringer Ingelheim GMBH and Eli Lilly & Co.'s Jardiance (empagliflozin) paves the way for other type 2 diabetes drugs to pick up CV benefit claims, even when outcomes trial results are mixed as to components of a primary endpoint.
On Dec. 2, FDA added a new indication to Jardiance's existing claim for glycemic control: to reduce the risk of...





